Comparison of triage strategies for HPV-positive women: Canadian cervical cancer screening trial results

Cancer Epidemiology Biomarkers and Prevention

Volumn 26, Issue 6, 2017, Pages 923-929

  Isidean, Sandra D ^a   Mayrand, Marie Helene ^a,b   Ramanakumar, Agnihotram V ^a   Rodrigues, Isabel ^b   Ferenczy, Alex ^c   Ratnam, Sam ^d   Coutlee, Fraņcois ^a,e   Franco, Eduardo L ^a  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^e CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANADA; CANCER SCREENING; COLPOSCOPY; COMPARATIVE STUDY; CYTOLOGY; DIAGNOSTIC TEST ACCURACY STUDY; EMERGENCY HEALTH SERVICE; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN TISSUE; MAJOR CLINICAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SQUAMOUS INTRAEPITHELIAL LESION OF THE CERVIX; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VIRUS LOAD; WART VIRUS; MASS SCREENING; METABOLISM; MIDDLE AGED; PAPILLOMAVIRIDAE; PATHOLOGY; PROCEDURES; UTERINE CERVIX TUMOR;

ADULT; AGED; CANADA; FEMALE; HUMANS; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRIDAE; UTERINE CERVICAL NEOPLASMS;

EID: 85020208393     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-16-0705     Document Type: Article

References (32)

1. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9.
2. ArbynM, Ronco G, Anttila A, Meijer CJ, Poljak M, Ogilvie G, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 2012;30:F88-99.
3. Castle PE, de Sanjose S, Qiao YL, Belinson JL, Lazcano-Ponce E, Kinney W. Introduction of human papillomavirus DNA screening in the world: 15 years of experience. Vaccine 2012;30:F117-22.
4. von Karsa L, Arbyn M, De Vuyst H, Ronco G, Schenck U, Segnan N, et al. European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination. Papillomavirus Res 2015;1:22-31.
5. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain JM, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol 2012;137:516-42.
6. Murphy J, Kennedy EB, Dunn S, McLachlin CM, Fung Kee Fung M, et al. Cervical screening: A guideline for clinical practice in Ontario. J Obstet Gynaecol Can 2012;34:453-8.
7. Wentzensen N, Schiffman M, Palmer T, Arbyn M. Triage of HPV positive women in cervical cancer screening. J Clin Virol 2016;76:S49-55.
8. Mayrand MH, Duarte-Franco E, Coutlee F, Rodrigues I, Walter SD, Ratnam S, et al. Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: design, methods and preliminary accrual results of the Canadian cervical cancer screening trial (CCCaST). Int J Cancer 2006;119:615-23.
9. Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007;357:1579-88.
10. Isidean SD, MayrandMH, Ramanakumar AV, Gilbert L, Reid SL, Rodrigues I, et al. Human papillomavirus testing versus cytology in primary cervical cancer screening: End-of-study and extended follow-up results from the Canadian cervical cancer screening trial. Int J Cancer 2016;139:2456-66.
11. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002;287:2114-9.
12. Coutlee F, Rouleau D, Petignat P, Ghattas G, Kornegay JR, Schlag P, et al. Enhanced detection and typing of human papillomavirus (HPV) DNA in anogenital samples with PGMY primers and the Linear array HPV genotyping test. J Clin Microbiol 2006;44:1998-2006.
13. Huh WK, Ault KA, Chelmow D, Davey DD, Goulart RA, Garcia FA, et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Gynecol Oncol 2015;136:178-82.
14. Cox JT, Castle PE, Behrens CM, Sharma A, Wright TC Jr, Cuzick J, et al. Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study. Am J Obstet Gynecol 2013;208:184 e1-184 e11.
15. de Sanjose S, Quint WG, Alemany L,Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: A retrospective cross-sectional worldwide study. Lancet Oncol 2010;11:1048-56.
16. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-analysis update. Int J Cancer 2007;121:621-32.
17. Rijkaart DC, Berkhof J, van Kemenade FJ, Coupe VM, Hesselink AT, Rozendaal L, et al. Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening. Int J Cancer 2012;130: 602-10.
18. Dijkstra MG, van Niekerk D, Rijkaart DC, van Kemenade FJ, Heideman DA, Snijders PJ, et al. Primary hrHPV DNA testing in cervical cancer screening: how to manage screen-positive women? A POBASCAM trial substudy. Cancer Epidemiol Biomarkers Prev 2014;23:55-63.
19. Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, Elfgren K, et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst 2009;101:88-99.
20. Mesher D, Szarewski A, Cadman L, Cubie H, Kitchener H, Luesley D, et al. Long-term follow-up of cervical disease in women screened by cytology and HPV testing: results from the HART study. Br J Cancer 2010;102: 1405-10.
21. Kotaniemi-Talonen L,Malila N, Nieminen P, Anttila A, Tarkkanen J, Laurila P, et al. Test positivity cutoff level of a high risk human papillomavirus test could be increased in routine cervical cancer screening. Int J Cancer 2008;123:2902-6.
22. Woodman CB, Collins SI, Young LS. The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer 2007;7:11-22.
23. Gravitt PE, KovacicMB,Herrero R, Schiffman M, Bratti C, Hildesheim A, et al. High load for most high risk human papillomavirus genotypes is associated with prevalent cervical cancer precursors but only HPV16 load predicts the development of incident disease. Int J Cancer 2007;121:2787-93.
24. Sherman ME, Wang SS, Wheeler CM, Rich L, Gravitt PE, Tarone R, et al. Determinants of human papillomavirus load among women with histological cervical intraepithelial neoplasia 3: dominant impact of surrounding low-grade lesions. Cancer Epidemiol Biomarkers Prev 2003;12: 1038-44.
25. Constandinou-Williams C, Collins SI, Roberts S, Young LS, Woodman CB, Murray PG, et al. Is human papillomavirus viral load a clinically useful predictive marker? A longitudinal study. Cancer Epidemiol Biomarkers Prev 2010;19:832-7.
26. Cuzick J, Ho L, Terry G, Kleeman M, Giddings M, Austin J, et al. Individual detection of 14 high risk human papilloma virus genotypes by the PapType test for the prediction of high grade cervical lesions. J Clin Virol 2014; 60:44-9.
27. Schiffman M, Burk RD, Boyle S, Raine-Bennett T, Katki HA, Gage JC, et al. A study of genotyping for management of human papillomavirus-positive, cytology-negative cervical screening results. J Clin Microbiol 2015;53: 52-9.
28. Schiffman M, Khan MJ, Solomon D, Herrero R, Wacholder S, Hildesheim A, et al. A study of the impact of adding HPV types to cervical cancer screening and triage tests. J Natl Cancer Inst 2005;97:147-50.
29. ArbynM, Roelens J,Martin-Hirsch P, Leeson S,Wentzensen N, et al. Use of HC2 to triage women with borderline and mild dyskaryosis in the UK. Br J Cancer 2011;105:877-80.
30. Stoler MH, Schiffman M, Atypical Squamous Cells of Undetermined Significance-Low-grade Squamous Intraepithelial Lesion Triage Study G. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA 2001;285:1500-5.
31. Richardson LA, El-Zein M, Ramanakumar AV, Ratnam S, Sangwa-Lugoma G, Longatto-Filho A, et al. HPV DNA testing with cytology triage in cervical cancer screening: Influence of revealing HPV infection status. Cancer Cytopathol 2015;123:745-54.
32. Bergeron C, Giorgi-Rossi P, Cas F, Schiboni ML, Ghiringhello B, Dalla Palma P, et al. Informed cytology for triaging HPV-positive women: substudy nested in the NTCC randomized controlled trial. J Natl Cancer Inst 2015;107. pii: dju423.